Anavex Life Sciences (AVXL) Cash & Equivalents (2010 - 2025)

Anavex Life Sciences (AVXL) has 16 years of Cash & Equivalents data on file, last reported at $131.7 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents rose 9.09% year-over-year to $131.7 million; the trailing twelve-month figure through Dec 2025 stood at $131.7 million (up 9.09% YoY), and the FY2025 full-year result was $102.6 million, down 22.4% from the prior year.
• Cash & Equivalents grew to $131.7 million in Q4 2025, from $102.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $157.6 million in Q2 2021 to a low of $75.9 million in Q1 2021.
• A 5-year average of $136.1 million and a median of $143.7 million in 2022 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents jumped 470.47% in 2021 and fell 27.09% in 2025, its largest moves.
• Tracing AVXL's Cash & Equivalents over 5 years: stood at $151.1 million in 2021, then dropped by 4.98% to $143.6 million in 2022, then gained by 0.1% to $143.8 million in 2023, then retreated by 15.99% to $120.8 million in 2024, then climbed by 9.09% to $131.7 million in 2025.
• Business Quant data shows AVXL's Cash & Equivalents at $131.7 million in Q4 2025, $102.6 million in Q3 2025, and $101.2 million in Q2 2025.